BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 36365206)

  • 1. Antisense Oligonucleotide Therapy for the Nervous System: From Bench to Bedside with Emphasis on Pediatric Neurology.
    Amanat M; Nemeth CL; Fine AS; Leung DG; Fatemi A
    Pharmaceutics; 2022 Nov; 14(11):. PubMed ID: 36365206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical advances of RNA therapeutics for treatment of neurological and neuromuscular diseases.
    Holm A; Hansen SN; Klitgaard H; Kauppinen S
    RNA Biol; 2022; 19(1):594-608. PubMed ID: 35482908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense oligonucleotides in neurological disorders.
    Wurster CD; Ludolph AC
    Ther Adv Neurol Disord; 2018; 11():1756286418776932. PubMed ID: 29854003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Making sense of antisense oligonucleotides: A narrative review.
    Goyal N; Narayanaswami P
    Muscle Nerve; 2018 Mar; 57(3):356-370. PubMed ID: 29105153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antisense therapies for neurological diseases].
    Pulst SM
    Nervenarzt; 2019 Aug; 90(8):781-786. PubMed ID: 31165208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcript-Targeted Therapy Based on RNA Interference and Antisense Oligonucleotides: Current Applications and Novel Molecular Targets.
    Barresi V; Musmeci C; Rinaldi A; Condorelli DF
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense oligonucleotides: the next frontier for treatment of neurological disorders.
    Rinaldi C; Wood MJA
    Nat Rev Neurol; 2018 Jan; 14(1):9-21. PubMed ID: 29192260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic antisense oligonucleotides for movement disorders.
    Doxakis E
    Med Res Rev; 2021 Sep; 41(5):2656-2688. PubMed ID: 32656818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Cell-Penetrating Peptide Delivery of Antisense Oligonucleotides for Therapeutic Efficacy in Spinal Muscular Atrophy.
    Hammond SM; Abendroth F; Gait MJ; Wood MJA
    Methods Mol Biol; 2019; 2036():221-236. PubMed ID: 31410800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medicinal Chemistry of Antisense Oligonucleotides for Therapeutic Use in SARS-CoV-2: Design Strategies and Challenges for Targeted Delivery.
    Nedaeinia R; Ranjbar M; Goli M; Etebari M; Safabakhsh S; Bayram H; Ferns GA; Tehrani HM; Salehi R
    Curr Med Chem; 2024 Jun; ():. PubMed ID: 38860908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense oligonucleotides: absorption, distribution, metabolism, and excretion.
    Shadid M; Badawi M; Abulrob A
    Expert Opin Drug Metab Toxicol; 2021 Nov; 17(11):1281-1292. PubMed ID: 34643122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antisense oligonucleotides: A primer.
    Scoles DR; Minikel EV; Pulst SM
    Neurol Genet; 2019 Apr; 5(2):e323. PubMed ID: 31119194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent Advances in Antisense Oligonucleotide Therapy in Genetic Neuromuscular Diseases.
    Verma A
    Ann Indian Acad Neurol; 2018; 21(1):3-8. PubMed ID: 29720791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemistry, structure and function of approved oligonucleotide therapeutics.
    Egli M; Manoharan M
    Nucleic Acids Res; 2023 Apr; 51(6):2529-2573. PubMed ID: 36881759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Better living through peptide-conjugated chemistry: next-generation antisense oligonucleotides.
    McNally EM; Leverson BD
    J Clin Invest; 2019 Nov; 129(11):4570-4571. PubMed ID: 31566581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Gene-specific treatment approaches in muscle diseases].
    Lehmann Urban D; Schneider I
    Nervenarzt; 2020 Apr; 91(4):318-323. PubMed ID: 32076754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug Discovery Perspectives of Antisense Oligonucleotides.
    Kim Y
    Biomol Ther (Seoul); 2023 May; 31(3):241-252. PubMed ID: 36859811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antisense oligonucleotides and other genetic therapies made simple.
    Rossor AM; Reilly MM; Sleigh JN
    Pract Neurol; 2018 Apr; 18(2):126-131. PubMed ID: 29455156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration.
    Monine M; Norris D; Wang Y; Nestorov I
    J Pharmacokinet Pharmacodyn; 2021 Oct; 48(5):639-654. PubMed ID: 33991294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High Concentration or Combined Treatment of Antisense Oligonucleotides for Spinal Muscular Atrophy Perturbed
    Wijaya YOS; Niba ETE; Nishio H; Okamoto K; Awano H; Saito T; Takeshima Y; Shinohara M
    Genes (Basel); 2022 Apr; 13(4):. PubMed ID: 35456491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.